We have developed a mathematical model that quantifies lymphocyte infection by human immunodeficiency virus (HIV) and lymphocyte protection by blocking agents such as soluble CD4. We use this model to suggest standardized parameters for quantifying viral infectivity and to suggest techniques for calculating these parameters from wellmixed infectivity assays. We discuss the implications of the model for our understanding of the infectious process and virulence of HIV in vivo.
Subsets of lymphocytes, monocytes, and macrophages expressing CD4 are the primary targets for infection by human immunodeficiency virus (HIV) (1) , and three overall steps have been suggested for the infective process. First, HIV diffuses to the cell surface; second, gpl20 (120-kDa glycoprotein) on the virus' surface and CD4 on the target cell's surface form a bimolecular complex; third, interactions involving CD4, gpl20, and gp41 promote fusion of HIV envelope with target cell membrane, resulting in entry of the viral core (2) (3) (4) . Given this mechanism, blocking some or all gpl20 molecules on the viral surface should inhibit infection (5) , and, consequently, soluble forms of CD4 (sCD4) have been suggested as potential therapeutic agents. In fact, several studies have demonstrated that sCD4 blocks HIV infection in vitro (6) (7) (8) (9) (10) .
In this paper, we develop a mathematical model quantifying the kinetics of target cell infection by HIV and target cell protection by sCD4. The model is concerned with infection from the fluid phase and does not address direct cell-to-cell transmission-e.g., syncytia formation (11) . We show how the model can be used to analyze the results of well-mixed viral infectivity assays and to determine parameters that influence the initial steps in infection. The model also has implications for our understanding of the infectious process and virulence of HIV in vivo and on the prospects for therapy with sCD4.
THE MODEL Consider a stock solution prepared from the supernatant of a cell culture infected with a particular strain of HIV. Such a stock solution can be regarded as a mixture of "homogeneous cohorts" of virions (i.e., populations of virions that were born simultaneously and that have been treated identically ever since). At birth, all members of a homogeneous cohort are assumed to be identical. A virion is said to remain "live" at time T, if it has neither participated in an infective event nor been nonspecifically killed. As time progresses, some cohort members will die and the "infectivity" of those remaining live will diverge due to random processes. Now suppose that V0 random members of a homogeneous cohort are selected at birth. These virions are allowed to preincubate for time Tp and are then inoculated at T = 0 into a chamber containing a large excess of CD4+ target cells (see Fig. 1A ). The objective of this procedure is to count the number of virions that successfully infect, I, which then yields the probability that a single virion will successfully infect, i I/V0. Considering each homogeneous cohort separately involves no loss of generality, since the behavior of a mixture of cohorts is obtained by taking a weighted average. Fig. 1B illustrates the random processes acting on a cohort.
Of these, blocking, shedding, and infection depend on gpl20; nonspecific killing does not. The "equivalent site approximation" from polymer chemistry gives a manageable formulation of Fig. 1B with a minimal loss of detail (15) (16) (17) . According to this approximation, each gpl20 molecule on the surface of a "live" virion has the same chance of being shed, of binding to CD4 on a target cell, or of binding to sCD4 in solution (i.e., each gpl20 has the same cross section for reaction). Furthermore, nonspecific killing operates independently on each live virion, regardless of its number of gpl20 molecules.
Let N be the initial number of gpl20 molecules on each virion at birth and let g be the probability that a particular gpl20 remains at a later time. Since gpl2Os can be either free or complexed with sCD4, g (F + C)/NV, where F and C are the numbers of free and complexed gpl20 molecules on live virions and V is the number oflive virions. Because ofthe equivalent site approximation, the probability that a live virion's surface will present exactly J gpl2Os is always given by a binomial distribution: P(J) = ()gJ( -g)NJ.
[1]
Since F/NV is the probability that a given gpl20 on a live virion is free and C/NV is the probability that a given gp120 [7] dt df -=-_y(3f-c)-uf-Af(l-f), [8] dt dc =y(ff-c)-ac + Afc. [9] dt The quantity i is the probability that an infectious virion born at -tp infects by time t. This is the main quantity of biological interest derived from infectivity assays.
Parameter Estimation. T lymphocytes used in viral infectivity assays typically display r = 2 x 104 CD4 receptors (18) . According to Berg and Purcell (19) , the probability that a viral gpl20 diffusing to a lymphocyte will find a CD4 receptor is rRb/(rRb + irRI) 0.8 (Table 1) . Electron microscope studies (20) (21) (22) estimate that 70-80 gpl20 complexes cover a mature virion (a single gpl20 complex covers -1/100th of a virion's surface). Therefore, we take N = 80 and the Smoluchowski formula for diffusional collision between two spherical particles (23) Experiments with other viruses indicate that k1 is unlikely to be more than 1000 times smaller than this upper limit (24) .
The Smoluchowski equation along with estimates from Table 1 also yield an upper limit for the forward rate constant of the blocking reaction: kf < 4ir(Dv + Db)(Rg + Rb) 3 .0 X 10-12 cm3 sec-1. Again, we would not expect kf to be more than 1000 times smaller than this upper limit.
The association constant between sCD4 and gpl20 (6, 25) ranges from 0.25 x 109 to 1.4 x 109 M-1. Accordingly, we take kassoc = kf/kr cm3.molecule-1. Given the fixed ratio kassoc, the reverse rate constant for the blocking reaction is kr = kf/kassoc -1.5 sec-1.
HIV-1 strains IIIB and RFII lose half of their infectivity in 4-6 hr at 37°C [P. L. Nara and J. Kessler, personal communication (using the assay in ref. 26) ]. This gives (ks + kn) 10-' sec-l molecule-1 to within a factor of 2. Unless specified, we use the above parameters for all numerical calculations.
Numerical Solutions. The kinetic processes in a viral infectivity assay. k1 is the rate constant for successful infective contact between viral gpl20 and CD4 on a target cell, defined on a per gpl20 basis. When a virion sheds all ofits gp120, it is considered live but not infectious. kn is the rate constant for nonspecific killing of virions, which includes mechanisms such as enzymatic degradation, dissolution by soaps, and neutralization by lipoprotein vesicles (12) . Complement does not appear to contribute to nonspecific killing of HIV (13) . The processes of infection and nonspecific killing result in the disappearance ofvirions together with their associated free and complexed gpl20s. k, is the rate constant for spontaneous disassociation of gpl20 from gp41 (14) . Although such "shedding" causes progressive inactivation of virions, it does not cause the actual disappearance of virions. kf and k, are the forward and reverse rate constants for gpl2O-sCD4 complex formation, respectively. These processes result in the masking and unmasking of gp120s but do not result in the net loss of gpl20 or in the disappearance of virions.
In Fig. 2A following this, the rate of target cell infection declines by a factor of 2-3 and, because of this decline, only 35% of the initial virions ultimately find target lymphocytes, a decline comparable to the blocking ratio.
In Fig. 2C , the concentration of sCD4 is 100-fold higher than in Fig. 2B . Consequently, equilibration of the blocker with gp120 occurs in only 3 x 10-3 sec and 199 of 200 gpl20 molecules are blocked. The rate ofinfectious events declines by the same proportion but the gpl20 shedding is unchanged. Therefore, the final proportion ofinfecting virions is only 0.6%. Fig. 2D shows the synergy of a high concentration of sCD4 with nonspecific killing of virus. Let us presume a rate constant for nonspecific killing, kn = 5 x 10-4 sec-1, that is 5-fold faster than the rate constant for gpl20 shedding, k, = 1 x 10-4 sec-1. As in Fig. 2C , binding of sCD4 to viral gp120 and the shedding of viral gpl20 are independent of nonspecific killing and occur on a "per live virion" basis. Nonspecific killing causes the disappearance of virions and so infection stops before virions shed all of their gpl20 molecules. As a result, the final proportion of infecting virions is diminished by a factor of 6 relative to Fig. 2C . Analytical Solutions. In Fig. 2 , viral gpl20 and sCD4 reach equilibrium rapidly compared to target cell infection, a property holding for the full range of physically relevant parameters. Consequently, the usual quasi steady-state approximation, kfBF krC, permits asymptotic solutions to Eqs. 6- 9. This approximation holds for time scales longer than the gpl2O-sCD4 equilibration time (derivation given in ref. 28 ).
Recall that g f + c is the nondimensional concentration of both free and complexed gpl20 on live virions. Because of the quasi steady-state approximation, c /8g/(l + P3) and f g/(l + *). Adding Eqs. 8 and 9 and applying these relations gives the Bernoulli equation: dg =-ag -A(1 + 3)-lg(l -g).
[10] dt The nondimensional form of the initial conditions at t = 0 is: io = 0, vo = exp{-(1 -a)tp} and go = exp{-o-Q}.
Eq. 10 is solvable by separation of variables, and integral forms of v(t) and i(t) are obtained as described elsewhere (28) The main use of Eqs. 12 and 13 is for design and analysis of experiments to measure the viral parameters kassoc, ks, kn, k1, and NVo. Fig. 3 illustrates the transition from the regime of Eq. 12 (small {) to the regime of Eq. 13 (large {). Consider an experiment to determine kasso. In such an experiment, I. would be measured at various values of the blocker concentration, B, with all other variables held constant. When target cell concentration L is moderate, Eq. 12 implies that a plot of Im(B = O)/Im(B > 0) versus B will be linear with slope = kass</(l + A) and intercept = 1. Fig. 4 shows five plots generated by numerical solutions of Eqs. 2-5, simulating such an experiment at different lymphocyte concentrations, L. Although the plots for all values of L appear linear, the fact that A ac L means that the slopes seriously underestimate kassoc except at the lowest cell concentrations. Hence, when determining kas.,c from the inhibition of viral infectivity, the experiment must be performed within the regime where the results are independent of cell concentration-i.e., A << 1.
Measuring the decay of viral infectivity with increasing preincubation times allows estimation of kn and k.. Fig. 5 shows five curves generated by numerical solution of Eqs. [2] [3] [4] [5] simulating such experiments at different choices of nonspecific killing, k,. Target cell concentration is made as large as possible and no blocker is added (B = 0). Under these conditions, it can be shown (Eq. 13) that the initial decay rate gives k0 and that the final decay rate gives k, + kn (Eq. 12).
The increase in decay rate with preincubation is a consequence of a fundamental kinetic difference between nonspecific killing and shedding. The former is a so-called "singlehit" process, whereas the latter is a "multi-hit" process inactivating the virus via incremental steps (i.e., loosing a few gpl20s makes little difference to the initial infection rate).
The lumped quantity, k. + k, is a direct measure ofthe ability of a viral strain to survive until it finds a target cell. A change in either k0 or ks + kn provides an objective measure of the potencies of viricidal agents. Conducting two "preincubation assays" as described above with different target cell concentrations yields estimates of both NVo and k1 (Fig. 6) . The quantity NVo is useful for estimating the number of "infectious" virions in the inoculum. The rate constant k1 is important because it quantifies the susceptibility of a particular target cell type to infection by a particular HIV strain. A decrease in k1 can be caused by a number of independent factors-e.g., a decrease in the surface density ofCD4, an increase in the viral uncoating and penetration time, or an increase in the abortive disassociation ofthe initial virus-target cell complex. (9, 31) the ratio of infection between "delayed control" and "experiment" yields kassoc 3.4 x 10-12 cm3-molecule1-. These results should be compared to values of kassoc measured for different analogs of sCD4 using direct physical methods (6, 25) and lymph node(L-108 cells-cm 3). Such extrapolation indicates a minimum therapeutic dose of =1000 ,ug-cm-3 of sCD4 to treat established infections in vivo. Even more pessimistically, target cell infection from direct cell-to-cell contacts (e.g., via major histocompatibility complex-restricted interactions) is probably less easily blocked than infection from the fluid medium. Experiments examining this situation are also required.
These results hold if the primary mechanism of action of sCD4 is simply to block the infective process by steric hindrance. Siliciano et al. (33) and Lanzavecchia et al. (34) indicate that sCD4 may protect CD4+ lymphocytes from indirect or autoimmune effects of gpl20. If this is the case, much lower concentrations of sCD4 may be oftherapeutic use.
The branching process can also be used for estimating the immune response that an anti-gpl20 vaccine must induce to protect against HIV infection. In this instance, kassoc is the association constant between gpl20 and neutralizing immunoglobulin, and Bmin is the minimum concentration of immunoglobulin required to extinguish the spread of infection. Assuming that neutralizing immunoglobulin has a kassoc identical to that of sCD4 (a rather high-affinity immunoglobulin), a molecular weight of -150,000, and Vni-300 yields Bmin 0.03 mg-cm-3 for blood. For lymph node, we calculate that -3 mg-cm-3 may be required to prevent growth of infection. Normally, serum contains =20 mg-cm-3 of all classes of immunoglobulin. Thus, an anti-gpl20 vaccine must induce and maintain an extremely high titer of blocking antibody.
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